Residual inflammation in patients with psoriasis treated with biologic therapy: findings from three prospective observational cohorts
收藏NIAID Data Ecosystem2026-05-02 收录
官方服务：
资源简介：
Supplementary Methods, Figures and Tables
应用场景：
创建时间：
2024-05-21
相关数据集
Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004–2023)
Biologics are essential in treating psoriasis. In recent years, the pathogenesis exploration and development of new target drugs have provided a more complete evidence-based foundation for the biologi
DataCite Commons2024-12-16 更新30
Long-term effectiveness, safety and adherence of bionaïve pustular psoriasis under secukinumab and ixekizumab treatment: 96-week analysis in the real-life setting
This is a real-world study to evaluate the long-term effectiveness and safety of IL-17A inhibitors for pustular psoriasis. Our findings illustrated sustained effectiveness responses through 96 weeks o
NIAID Data Ecosystem10
Dataset related to article "Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)""
Abstract Background: Guselkumab is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete res
NIAID Data Ecosystem10
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study
Bimekizumab is a novel interleukin (IL)-17A/IL-17F inhibitor approved for the treatment of moderate-to-severe plaque psoriasis in adult patients. While its efficacy and safety have been demonstrated i
NIAID Data Ecosystem10
Secukinumab demonstrates efficacy, safety and tolerability upon administration by 2 mL autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial
Secukinumab demonstrates efficacy, safety and tolerability upon administration by 2 mL autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controll
NIAID Data Ecosystem10
